Lymphoma combo drug study pulled before it even started
NCT ID NCT04607772
First seen Nov 01, 2025 · Last updated May 25, 2026 · Updated 29 times
Summary
This study was designed to test the safety and effectiveness of combining the drug selinexor with other treatments for people whose diffuse large B-cell lymphoma had come back or stopped responding to therapy. It planned to enroll adults with this type of lymphoma who had already received 1 to 3 prior treatments. However, the study was withdrawn before any participants were enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Baylor Clinic - Mcnair Center
Houston, Texas, 77030, United States
-
California Cancer Associates for Research and Excellence
Encinitas, California, 92024, United States
-
Karmanos Cancer Institute
Detroit, Michigan, 48021, United States
-
Loyola University Medical Center
Maywood, Illinois, 60153, United States
-
Mission Cancer + Blood
Des Moines, Iowa, 50309, United States
-
Roswell Park Comprehensive Cancer Center
Buffalo, New York, 14263, United States
-
UC San Diego Moores Cancer Center
La Jolla, California, 92093, United States
-
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232, United States
-
US Oncology - Northwest Cancer Specialists
Vancouver, Washington, 98684, United States
-
US Oncology - Oncology Associates of Oregon
Eugene, Oregon, 97401, United States
-
US Oncology - Prisma Health
Greenville, South Carolina, 29605, United States
-
US Oncology - Rocky Mountain Cancer Center
Aurora, Colorado, 80012, United States
-
US Oncology - Texas Oncology Austin Midtown
Austin, Texas, 78705, United States
-
University of Arizona
Tucson, Arizona, 85724, United States
-
University of California Irvine
Orange, California, 92868, United States
-
University of Michigan Health System
Ann Arbor, Michigan, 48109, United States
-
University of Nebraska Medical Center
Omaha, Nebraska, 68198, United States
-
University of Texas Southwestern
Dallas, Texas, 75390, United States
Conditions
Explore the condition pages connected to this study.